|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
JPH02500329A
(ja)
|
1987-05-21 |
1990-02-08 |
クリエイテイブ・バイオマリキユールズ・インコーポレーテツド |
ターゲット化多機能蛋白質
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
US6322789B1
(en)
|
1991-08-26 |
2001-11-27 |
Epimmune, Inc. |
HLA-restricted hepatitis B virus CTL epitopes
|
|
JP3540315B2
(ja)
|
1991-09-23 |
2004-07-07 |
メディカル リサーチ カウンシル |
キメラ抗体の製造−組合せアプローチ
|
|
DE69233528T2
(de)
|
1991-11-25 |
2006-03-16 |
Enzon, Inc. |
Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
|
|
DE614989T1
(de)
|
1993-02-17 |
1995-09-28 |
Morphosys Proteinoptimierung |
Verfahren für in vivo Selektion von Ligandenbindende Proteine.
|
|
US5635363A
(en)
|
1995-02-28 |
1997-06-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
|
|
US5869270A
(en)
|
1996-01-31 |
1999-02-09 |
Sunol Molecular Corporation |
Single chain MHC complexes and uses thereof
|
|
US6211342B1
(en)
|
1996-07-18 |
2001-04-03 |
Children's Hospital Medical Center |
Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
|
|
US20050003431A1
(en)
|
1996-08-16 |
2005-01-06 |
Wucherpfennig Kai W. |
Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
|
|
US6218363B1
(en)
|
1996-08-28 |
2001-04-17 |
Thomas Jefferson University |
MHC peptides and methods of use
|
|
US7098306B2
(en)
|
1997-02-13 |
2006-08-29 |
The Regents Of The University Of California |
Method and compositions for treating hepatocellular cancer
|
|
JP3816959B2
(ja)
|
1997-02-13 |
2006-08-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
肝細胞癌の予防および処置
|
|
US6268411B1
(en)
|
1997-09-11 |
2001-07-31 |
The Johns Hopkins University |
Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
|
|
DE69839443D1
(de)
|
1997-05-08 |
2008-06-19 |
Biomira Inc |
Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen
|
|
US20030007978A1
(en)
|
1997-09-16 |
2003-01-09 |
Burrows Gregory G. |
Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
|
|
US6696304B1
(en)
|
1999-02-24 |
2004-02-24 |
Luminex Corporation |
Particulate solid phase immobilized protein quantitation
|
|
AU779395B2
(en)
|
1999-04-30 |
2005-01-20 |
Institut De Recherche Cliniques De Montreal (Ircm) |
Mutant human CD80 and compositions for and methods of making and using the same
|
|
US20020006664A1
(en)
|
1999-09-17 |
2002-01-17 |
Sabatini David M. |
Arrayed transfection method and uses related thereto
|
|
US6287860B1
(en)
|
2000-01-20 |
2001-09-11 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of MEKK2 expression
|
|
CN1430728A
(zh)
|
2000-05-25 |
2003-07-16 |
苏诺尔分子公司 |
T细胞受体交互作用的调节
|
|
US20020122820A1
(en)
|
2001-01-16 |
2002-09-05 |
Hildebrand William H. |
Soluble MHC artificial antigen presenting cells
|
|
US6800748B2
(en)
|
2001-01-25 |
2004-10-05 |
Large Scale Biology Corporation |
Cytoplasmic inhibition of gene expression and expression of a foreign protein in a monocot plant by a plant viral vector
|
|
EP2336167B1
(en)
|
2001-03-14 |
2019-05-29 |
Dako Denmark A/S |
MHC molecule constructs and their uses for diagnosis and therapy
|
|
WO2002093129A2
(en)
|
2001-05-15 |
2002-11-21 |
University Of Medicine & Dentistry Of New Jersey |
Methods for analyzing interactions between proteins in live and intact cells
|
|
WO2002099070A2
(en)
|
2001-06-04 |
2002-12-12 |
Corixa Corporation |
Compositions and methods for high-level, large-scale production of recombinant proteins
|
|
US20030017134A1
(en)
|
2001-06-19 |
2003-01-23 |
Technion Research And Development Foundation Ltd. |
Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
|
|
AU2002368044A1
(en)
|
2001-06-22 |
2004-04-19 |
Maxygen, Inc. |
Co-stimulatory molecules
|
|
WO2003006632A2
(en)
|
2001-07-12 |
2003-01-23 |
Canvac |
Methods and compisitions for activation human t cells in vitro
|
|
WO2003040307A2
(en)
|
2001-07-27 |
2003-05-15 |
Human Genome Sciences, Inc. |
Heteromultimeric tnf ligand family members
|
|
EP1454138B1
(en)
|
2001-12-04 |
2012-01-18 |
Merck Patent GmbH |
Immunocytokines with modulated selectivity
|
|
CA2479212A1
(en)
|
2002-03-15 |
2003-09-25 |
Brigham And Women's Hospital, Inc. |
Central airway administration for systemic delivery of therapeutics
|
|
US8895020B2
(en)
|
2002-04-19 |
2014-11-25 |
Washington University |
Single chain trimers and uses therefor
|
|
WO2004022593A2
(en)
|
2002-09-09 |
2004-03-18 |
Nautilus Biotech |
Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
|
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
|
CA2516832A1
(en)
|
2003-02-27 |
2004-09-10 |
Theravision Gmbh |
A molecule which binds cd80 and cd86
|
|
AU2003901876A0
(en)
|
2003-04-17 |
2003-05-08 |
The Macfarlane Burnet Institute For Medical Research And Public Health |
Viral vector
|
|
US20050042641A1
(en)
|
2003-05-27 |
2005-02-24 |
Cold Spring Harbor Laboratory |
In vivo high throughput selection of RNAi probes
|
|
US7696306B2
(en)
|
2003-07-11 |
2010-04-13 |
Board of Agents of the University of Nebraska |
Compositions and methods for preventing or treating cancer
|
|
WO2005044982A2
(en)
|
2003-09-05 |
2005-05-19 |
Oregon Health & Science University |
Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
|
|
US7470513B2
(en)
|
2003-11-10 |
2008-12-30 |
Academia Sinica |
Risk assessment for adverse drug reactions
|
|
KR20070003934A
(ko)
|
2004-03-05 |
2007-01-05 |
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 |
치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
|
|
DE102004014983A1
(de)
|
2004-03-26 |
2005-10-20 |
Univ Stuttgart |
Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
|
|
US20060034850A1
(en)
|
2004-05-27 |
2006-02-16 |
Weidanz Jon A |
Antibodies as T cell receptor mimics, methods of production and uses thereof
|
|
US7670595B2
(en)
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
CA2523032A1
(en)
|
2005-10-07 |
2007-04-07 |
Immunovaccine Technologies Inc. |
Vaccines for cancer therapy
|
|
RU2008123518A
(ru)
|
2005-11-10 |
2009-12-20 |
Ресептор Байолоджикс, Инк. (Us) |
Способы получения изоформ рецепторов и лигандов
|
|
US7943133B2
(en)
|
2006-02-02 |
2011-05-17 |
Boston Biocom Llc |
Mesothelin antibody protein fusions and methods of use
|
|
CA2644712C
(en)
|
2006-03-06 |
2016-09-13 |
Amunix, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
US8518697B2
(en)
|
2006-04-04 |
2013-08-27 |
Washington University |
Single chain trimers and uses therefor
|
|
WO2007136778A2
(en)
|
2006-05-19 |
2007-11-29 |
Teva Pharmaceutical Industries, Ltd. |
Fusion proteins, uses thereof and processes for producing same
|
|
EP1889851A1
(en)
|
2006-08-18 |
2008-02-20 |
Charite Universitätsmedizin-Berlin |
PAX2 and PAX8 as targets for immunologic and molecular tumour treatment strategies
|
|
US8992937B2
(en)
|
2006-08-28 |
2015-03-31 |
Washington University |
Disulfide trap MHC class I molecules and uses therefor
|
|
RU2481398C2
(ru)
|
2006-12-28 |
2013-05-10 |
Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. |
Hla-a*1101-ограниченный пептид wt1 и содержащая его фармацевтическая композиция
|
|
CN101657213B
(zh)
|
2007-02-15 |
2014-02-26 |
曼康公司 |
用于增强t细胞应答的方法
|
|
WO2008113970A2
(en)
|
2007-03-16 |
2008-09-25 |
Ucl Business Plc |
Peptides
|
|
EP2155782A2
(en)
|
2007-03-26 |
2010-02-24 |
Dako Denmark A/S |
Mhc peptide complexes and uses thereof in infectious diseases
|
|
US9394571B2
(en)
|
2007-04-27 |
2016-07-19 |
Pfenex Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
CA2695374A1
(en)
|
2007-08-15 |
2009-02-19 |
Amunix, Inc. |
Compositions and methods for modifying properties of biologically active polypeptides
|
|
US8926961B2
(en)
|
2007-10-03 |
2015-01-06 |
Board Of Trustees Of The University Of Arkansas |
HPV E6 protein T cell epitopes and uses thereof
|
|
CN101418309B
(zh)
|
2007-10-23 |
2011-05-04 |
中国农业科学院上海兽医研究所 |
柔嫩艾美耳球虫蛋白质二硫键异构酶基因的克隆、表达及应用
|
|
DE102008023820A1
(de)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
TW201008574A
(en)
|
2008-08-19 |
2010-03-01 |
Oncotherapy Science Inc |
INHBB epitope peptides and vaccines containing the same
|
|
WO2010037395A2
(en)
|
2008-10-01 |
2010-04-08 |
Dako Denmark A/S |
Mhc multimers in cancer vaccines and immune monitoring
|
|
EP2184070A1
(en)
|
2008-11-07 |
2010-05-12 |
Hla-G Technologies |
HLA-G proteins and pharmaceutical uses thereof
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
WO2010085495A1
(en)
|
2009-01-21 |
2010-07-29 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
DK3178835T3
(da)
|
2009-02-03 |
2019-06-24 |
Amunix Pharmaceuticals Inc |
Forlængede rekombinante polypeptider og sammensætninger omfattende samme
|
|
US9359424B2
(en)
|
2009-06-25 |
2016-06-07 |
Commissariat A L'energie Atomique Et Aux Energies Alternatives |
Multimeric polypeptides of HLA-G including alpha1-alpha3 monomers and pharmaceutical uses thereof
|
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
EP2593551B1
(en)
|
2010-07-15 |
2016-09-14 |
Technion Research & Development Foundation Ltd. |
Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
|
|
JP6251570B2
(ja)
|
2010-09-21 |
2017-12-20 |
アルター・バイオサイエンス・コーポレーション |
多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
|
|
WO2012088446A1
(en)
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
CN105440123B
(zh)
*
|
2011-02-10 |
2020-10-09 |
罗切格利卡特公司 |
突变体白介素-2多肽
|
|
WO2012127464A2
(en)
|
2011-03-23 |
2012-09-27 |
Gavish-Galilee Bio Applications Ltd |
Constitutively activated t cells for use in adoptive cell therapy
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
PL2723773T3
(pl)
|
2011-06-22 |
2018-07-31 |
F.Hoffmann-La Roche Ag |
Eliminacja komórek docelowych przez obecne w krążeniu, swoiste dla wirusa, cytotoksyczne limfocyty T z wykorzystaniem kompleksów zawierających MHC klasy I
|
|
RU2657440C2
(ru)
|
2011-06-30 |
2018-06-13 |
Джензим Корпорейшн |
Ингибиторы т-клеточной активации
|
|
US9494588B2
(en)
|
2011-08-30 |
2016-11-15 |
Jacobs University Bremen Ggmbh |
Gene coded for a MHC class I molecule, plasmid, expression system protein, multimer, reagent and kit to analyze a T cell frequency
|
|
US8956619B2
(en)
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
|
BR112014012819B1
(pt)
|
2011-11-28 |
2022-08-16 |
Merck Patent Gmbh |
Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
|
|
EP3520810A3
(en)
|
2012-01-13 |
2019-11-06 |
Memorial Sloan-Kettering Cancer Center |
Immunogenic wt1 peptides and use thereof
|
|
EP2809345A4
(en)
|
2012-02-03 |
2015-11-25 |
Univ Emory |
IMMUNOSTIMULATING COMPOSITIONS, PARTICLES THEREFOR, AND USES THEREFOR
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
HK1211949A1
(en)
|
2012-11-30 |
2016-06-03 |
罗切格利卡特公司 |
Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins
|
|
SG11201504558TA
(en)
|
2012-12-11 |
2015-07-30 |
Einstein Coll Med |
Methods for high throughput receptor:ligand identification
|
|
JP6475167B2
(ja)
|
2012-12-21 |
2019-02-27 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ジスルフィド結合した多価ｍｈｃクラスｉを含む多機能タンパク質
|
|
US10815273B2
(en)
|
2013-01-15 |
2020-10-27 |
Memorial Sloan Kettering Cancer Center |
Immunogenic WT-1 peptides and methods of use thereof
|
|
LT2945647T
(lt)
|
2013-01-15 |
2021-02-25 |
Memorial Sloan Kettering Cancer Center |
Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai
|
|
EP2948475A2
(en)
|
2013-01-23 |
2015-12-02 |
AbbVie Inc. |
Methods and compositions for modulating an immune response
|
|
EP3587448B1
(en)
|
2013-03-15 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2968450A4
(en)
|
2013-03-15 |
2016-10-26 |
Angelica Therapeutics Inc |
MODIFIED TOXINS
|
|
WO2014157692A1
(ja)
|
2013-03-29 |
2014-10-02 |
大日本住友製薬株式会社 |
Ｗｔ１抗原ペプチドコンジュゲートワクチン
|
|
WO2014185387A1
(ja)
|
2013-05-13 |
2014-11-20 |
株式会社癌免疫研究所 |
免疫療法の臨床効果の予測法
|
|
GB201311475D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Polypeptides
|
|
MX370565B
(es)
|
2013-07-19 |
2019-12-17 |
Vib Vzw |
Miembros de la familia tnf modificados dirigidos.
|
|
US10273301B2
(en)
|
2013-12-24 |
2019-04-30 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
|
AU2015209540B2
(en)
|
2014-01-21 |
2021-05-13 |
Albert Einstein College Of Medicine, Inc. |
Cellular platform for rapid and comprehensive T-cell immunomonitoring
|
|
WO2015130766A1
(en)
|
2014-02-25 |
2015-09-03 |
Memorial Sloan-Kettering Cancer Center |
Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
|
|
EP3112378B1
(en)
|
2014-02-26 |
2020-06-24 |
Tella, Inc. |
Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
|
|
JP6592505B2
(ja)
|
2014-04-24 |
2019-10-16 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
|
|
JP6652932B2
(ja)
*
|
2014-06-18 |
2020-02-26 |
アルバート アインシュタイン カレッジ オブ メディシン |
ｓｙｎＴａｃポリペプチド及びその使用
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
KR102493543B1
(ko)
|
2014-07-21 |
2023-01-30 |
데리니아, 인크. |
자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
|
|
EP3180018B1
(en)
*
|
2014-08-12 |
2019-07-24 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
|
CA2958578A1
(en)
|
2014-08-21 |
2016-02-25 |
The General Hospital Corporation |
Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
|
|
ES2774380T3
(es)
|
2014-08-29 |
2020-07-20 |
Hoffmann La Roche |
Politerapia de inmunocitocinas de variante de IL-2 dirigida a tumor y anticuerpos frente a PD-L1 humano
|
|
SG11201707182WA
(en)
|
2015-03-05 |
2017-10-30 |
Hutchinson Fred Cancer Res |
Immunomodulatory fusion proteins and uses thereof
|
|
EP3286222A4
(en)
|
2015-03-23 |
2018-08-08 |
The Johns Hopkins University |
Hla-restricted epitopes encoded by somatically mutated genes
|
|
IL304950A
(en)
|
2015-04-10 |
2023-10-01 |
Amgen Inc |
Interleukin for the expansion of myotonic control T-2 cells
|
|
SMT202100467T1
(it)
|
2015-04-17 |
2021-09-14 |
Alpine Immune Sciences Inc |
Proteine immunomodulatorie con affinità regolabili
|
|
ES3055030T3
(en)
|
2015-05-06 |
2026-02-09 |
Uti Lp |
Nanoparticle compositions for sustained therapy
|
|
MX383464B
(es)
|
2015-07-13 |
2025-03-14 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
|
|
WO2017008844A1
(en)
|
2015-07-14 |
2017-01-19 |
Biontech Ag |
Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof
|
|
CN106397592A
(zh)
|
2015-07-31 |
2017-02-15 |
苏州康宁杰瑞生物科技有限公司 |
针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
|
|
AU2016303497A1
(en)
|
2015-07-31 |
2018-03-01 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immuno-oncology therapies
|
|
CN106565836B
(zh)
|
2015-10-10 |
2020-08-18 |
中国科学院广州生物医药与健康研究院 |
高亲和力的可溶性pdl-1分子
|
|
HUE059694T2
(hu)
|
2015-11-20 |
2022-12-28 |
Memorial Sloan Kettering Cancer Center |
Készítmény rák kezelésére
|
|
US20190365656A1
(en)
|
2016-01-04 |
2019-12-05 |
Cour Pharmaceuticals Development Company, Inc. |
Particles encapsulating fusion proteins containing linked epitopes
|
|
RU2018130525A
(ru)
|
2016-01-27 |
2020-02-27 |
Цсл Беринг Ленгнау Аг |
РЕКОМБИНАНТНЫЕ Fc-МУЛЬТИМЕРЫ IgG
|
|
CA3014458A1
(en)
*
|
2016-03-02 |
2017-09-08 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
WO2017151940A2
(en)
|
2016-03-03 |
2017-09-08 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
SG11201808552XA
(en)
*
|
2016-05-18 |
2018-10-30 |
Cue Biopharma Inc |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
IL262606B2
(en)
*
|
2016-05-18 |
2023-04-01 |
Albert Einstein College Medicine Inc |
pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them
|
|
US20180127481A1
(en)
|
2016-11-09 |
2018-05-10 |
Uti Limited Partnership |
RECOMBINANT pMHC CLASS II MOLECULES
|
|
CN110325205B
(zh)
|
2016-12-22 |
2023-08-15 |
库尔生物制药有限公司 |
T细胞调节性多聚体多肽及其使用方法
|
|
US11851471B2
(en)
|
2017-01-09 |
2023-12-26 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
KR20190123328A
(ko)
|
2017-03-09 |
2019-10-31 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
암 백신
|
|
KR20240005989A
(ko)
|
2017-03-15 |
2024-01-12 |
큐 바이오파마, 인크. |
면역 반응을 조절하는 방법
|
|
US11725210B2
(en)
|
2017-03-17 |
2023-08-15 |
Fred Hutchinson Cancer Center |
Immunomodulatory fusion proteins and uses thereof
|
|
EP3446702A1
(en)
|
2017-08-23 |
2019-02-27 |
Medizinische Hochschule Hannover |
Synthetic vaccine
|
|
MX2020002596A
(es)
|
2017-09-07 |
2020-07-20 |
Cue Biopharma Inc |
Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos.
|
|
EP3678677A4
(en)
|
2017-09-07 |
2021-06-16 |
Cue Biopharma, Inc. |
ANTIGEN-PRESENTING POLYPEPTIDES AND METHOD FOR THEIR USE
|
|
WO2019051127A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
|
|
WO2019051126A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF
|
|
US11952408B2
(en)
|
2017-10-03 |
2024-04-09 |
Juno Therapeutics, Inc. |
HPV-specific binding molecules
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
EP3755711A4
(en)
|
2018-02-20 |
2021-11-24 |
Technion Research & Development Foundation Limited |
IMMUNOTHERAPEUTIC COMPOSITION FOR THE TREATMENT OF CANCER
|
|
WO2020132136A1
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2020132135A1
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
TWI856047B
(zh)
|
2018-12-19 |
2024-09-21 |
美商信號生物製藥公司 |
多聚體ｔ細胞調節多肽及其使用方法
|
|
EP3897746A4
(en)
|
2018-12-19 |
2022-10-26 |
Cue Biopharma, Inc. |
MULTIMERIC T LYMPHOCYTE MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
|
|
WO2020181062A1
(en)
|
2019-03-06 |
2020-09-10 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
JP7691927B2
(ja)
|
2019-03-06 |
2025-06-12 |
キュー バイオファーマ， インコーポレイテッド |
Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
|
|
KR20220015382A
(ko)
|
2019-05-29 |
2022-02-08 |
큐 바이오파마, 인크. |
다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법
|
|
JP7778571B2
(ja)
|
2019-06-05 |
2025-12-02 |
アッシャー バイオセラピューティクス， インコーポレイテッド |
免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体
|
|
JP2022536581A
(ja)
|
2019-06-19 |
2022-08-18 |
キュー バイオファーマ， インコーポレイテッド |
多量体ｔ細胞調節性ポリペプチド及びその使用方法
|
|
EP4030897A4
(en)
|
2019-09-20 |
2023-10-18 |
Cue Biopharma, Inc. |
T-cell modulatory polypeptides and methods of use thereof
|
|
CN114599674A
(zh)
|
2019-10-23 |
2022-06-07 |
库尔生物制药有限公司 |
T细胞调节嵌合分子及其使用方法
|
|
WO2021081232A1
(en)
|
2019-10-23 |
2021-04-29 |
Cue Biopharma, Inc. |
Modified cytotoxic t cells and methods of use thereof
|
|
WO2021113297A1
(en)
|
2019-12-02 |
2021-06-10 |
Regeneron Pharmaceuticals, Inc. |
Peptide-mhc ii protein constructs and uses thereof
|
|
IL293978A
(en)
|
2019-12-20 |
2022-08-01 |
Regeneron Pharma |
New il2 agonists and methods of using them
|
|
CN115176015A
(zh)
|
2020-02-28 |
2022-10-11 |
国立大学法人金泽大学 |
免疫调节法、免疫调节用核酸组合物及其用途
|
|
GB202005617D0
(en)
|
2020-04-17 |
2020-06-03 |
Adaptimmune Ltd |
Improved t cell manufacturing process
|
|
IL296209A
(en)
|
2020-05-12 |
2022-11-01 |
Cue Biopharma Inc |
Multimeric t-cell modulatory polypeptides and methods of using them
|
|
CN113823723A
(zh)
|
2020-06-18 |
2021-12-21 |
光宝光电(常州)有限公司 |
发光二极管封装结构
|
|
WO2022015880A2
(en)
|
2020-07-14 |
2022-01-20 |
Cue Biopharma, Inc. |
T-cell modulatory polypeptides with conjugation sites and methods of use thereof
|
|
KR20230112632A
(ko)
|
2020-10-23 |
2023-07-27 |
애셔 바이오테라퓨틱스, 인크. |
면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
|
|
JP2023553216A
(ja)
|
2020-12-09 |
2023-12-20 |
アシャ バイオセラピューティクス，インク． |
遺伝子操作細胞療法のための標的化サイトカイン構築物
|
|
WO2022125694A1
(en)
|
2020-12-09 |
2022-06-16 |
Asher Biotherapeutics, Inc. |
Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function
|